|
1
|
Khosravifar S, Ghalebandi M, Abounoori M, Aloosh O, Rahiminia A, Khosravifar S, Afshar H, Aloosh A. The association between sleep quality, health status, and disability due to breathlessness in COPD patients. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
|
2
|
Rahmatpour Rokni G, Shiran M, Abounoori M, Houshmand G, Babakhanian M, Godazandeh G, Bayat S, Pazyar N, Abedi M, Khorshidi F, Yari F, Ghafouri Z, Patil A, Goldust M, Mirmohammadi Langari L. Effects of metformin on autoimmune immunoglobins and interferon-γ in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial. Clin Exp Dermatol 2021; 47:110-113. [PMID: 34236726 DOI: 10.1111/ced.14832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 06/30/2021] [Accepted: 07/02/2021] [Indexed: 11/27/2022]
Abstract
The management of pemphigus vulgaris (PV) is challenging. This study aimed to evaluate the immunomodulating effects of metformin on PV. The study was conducted in two phases: in the first phase, patients received routine first-line treatment (prednisolone plus azathioprine) for 2 months, then in the second phase, metformin was added to this regimen for another 2 months. After addition of metformin to the first-line medications, significant reductions were seen in serum IgG1 (reduced from 534.92 ± 134.83 mg/dL to 481.58 ± 130.46 mg/dL, P < 0.001), IgG4 (51.83 ± 27.26 mg/dL to 44.50 ± 26.05 mg/dL, P < 0.001) and interferon-γ (277.99 ± 108.71 pg/mL to 45.05 ± 17.080 pg/mL, P = 0.03) concentrations. The suppressant effect of metformin was greatest on IgG4 (coefficient of variation 1.28), the dominant subclass of IgG involved in PV. Metformin could have immunomodulating effects on PV with controlling effects on steroid complications.
Collapse
Affiliation(s)
- G Rahmatpour Rokni
- Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - M Shiran
- Department of Pharmacology, Immuno-Genetics Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - M Abounoori
- Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - G Houshmand
- Immunogenetics Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - M Babakhanian
- Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
| | - G Godazandeh
- Department of Thoracic Surgery, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
| | - S Bayat
- Student Research Committee, Department of Internal Medicine, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - N Pazyar
- Department of Dermatology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - M Abedi
- Faculty of Medicine, Azad University of Mazandaran, Sari, Iran
| | - F Khorshidi
- Faculty of Medicine, Azad University of Mazandaran, Sari, Iran
| | - F Yari
- Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Z Ghafouri
- College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada
| | - A Patil
- Department of Pharmacology, Dr DY Patil Medical College, Navi Mumbai, India
| | - M Goldust
- Department of Dermatology, University Medical Center Mainz, Mainz, Germany
| | - L Mirmohammadi Langari
- Microbial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|